News | April 24, 2008

SCAI, ACC Return to Individual Scientific Sessions in 2009

April 25, 2008 - The Society for Cardiovascular Angiography and Interventions (SCAI) and the American College of Cardiology (ACC) will return to the traditional individual meeting formats for both the SCAI Annual Scientific Sessions and i2 Summit in 2009, in response to SCAI members' request for more a intimate meeting.

In 2008, SCAI and ACC partnered to hold the SCAI Annual Scientific Sessions in Partnership with ACCi2 Summit (SCAI-ACCi2), held in conjunction with ACC's Annual Scientific Session in Chicago.

"This year's SCAI-ACCi2 meeting was a strong achievement, particularly in terms of securing increased positive attention for our field,"? said SCAI President Bonnie H. Weiner, M.D. "Yet SCAI's members are enthusiastic about a return to the intimacy of a meeting with a targeted focus on high-level interventional cardiology. We look forward to continuing to look for ways to provide venues to educate both general and interventional cardiology communities so that we may learn from one another and, as always, provide the most optimal care to all cardiology patients."

"The ACC continues to be committed to serving the needs of our interventional members, and we look forward to a successful 2009 ACC i2 Summit that will build upon the success of this meeting over the past three years," said W. Douglas Weaver, president of the ACC. "Our relationship with SCAI remains strong, and we will continue to collaborate on various initiatives including education, guidelines and advocacy."

For more information: www.scai.org and www.acc.org

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init